Initiates Coverage on vTv Therapeutics (NASDAQ:VTVT)

Analysts at assumed coverage on shares of vTv Therapeutics (NASDAQ:VTVTGet Free Report) in a note issued to investors on Sunday. The brokerage set a “hold” rating on the biotechnology company’s stock.

vTv Therapeutics Stock Performance

VTVT stock opened at $0.35 on Friday. The company has a fifty day moving average price of $0.43 and a 200-day moving average price of $0.62. The company has a market capitalization of $36.60 million, a P/E ratio of -1.30 and a beta of -0.01. vTv Therapeutics has a 52-week low of $0.35 and a 52-week high of $1.05.

Institutional Investors Weigh In On vTv Therapeutics

Several large investors have recently modified their holdings of VTVT. Prudential Financial Inc. acquired a new stake in shares of vTv Therapeutics during the second quarter worth $30,000. Millennium Management LLC grew its holdings in vTv Therapeutics by 12.0% in the second quarter. Millennium Management LLC now owns 138,683 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 14,845 shares during the period. Pathstone Family Office LLC acquired a new stake in vTv Therapeutics in the third quarter worth $116,000. Finally, State Street Corp grew its holdings in vTv Therapeutics by 268.7% in the second quarter. State Street Corp now owns 206,145 shares of the biotechnology company’s stock worth $155,000 after purchasing an additional 150,228 shares during the period. 3.36% of the stock is currently owned by institutional investors and hedge funds.

vTv Therapeutics Company Profile

(Get Free Report)

vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company's lead drug candidate is TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis.

Featured Articles

Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with's FREE daily email newsletter.